Merck & Co., Inc. (ETR:6MK)
71.50
-0.70 (-0.97%)
Sep 10, 2025, 4:40 PM CET
Merck & Co. Revenue
Merck & Co. had revenue of $15.81B USD in the quarter ending June 30, 2025, a decrease of -1.90%. This brings the company's revenue in the last twelve months to $63.62B, up 1.82% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$63.62B
Revenue Growth
+1.82%
P/S Ratio
3.31
Revenue / Employee
$848.21K
Employees
75,000
Market Cap
179.08B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Fresenius Medical Care AG | 19.52B |
Sartorius Aktiengesellschaft | 3.47B |
Fielmann Group AG | 2.40B |
Carl Zeiss Meditec AG | 2.18B |
Merck & Co. News
- 2 days ago - Merck & Co., Inc. (MRK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 2 days ago - Summit Therapeutics: Dethroning Merck Was Never Going To Be Straightforward - Seeking Alpha
- 2 days ago - Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences - Benzinga
- 3 days ago - Merck (MRK) and Daiichi Sankyo's Ifinatamab Deruxtecan Shows Promise in Lung Cancer Trial - GuruFocus
- 3 days ago - Merck & Co Inc (MRK) Announces Promising Results from Phase 2 Trial for Small Cell Lung ... - GuruFocus
- 4 days ago - 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 9% (Sept. 2025) - Seeking Alpha
- 4 days ago - September Dogs Of The Dow Unleash One Ideal 'Safer' DiviDog - Seeking Alpha
- 6 days ago - Merck & Co., Inc. (MRK) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha